1. Home
  2. EDSA vs HYFM Comparison

EDSA vs HYFM Comparison

Compare EDSA & HYFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • HYFM
  • Stock Information
  • Founded
  • EDSA 2015
  • HYFM 1977
  • Country
  • EDSA Canada
  • HYFM United States
  • Employees
  • EDSA N/A
  • HYFM N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • HYFM Industrial Machinery/Components
  • Sector
  • EDSA Health Care
  • HYFM Industrials
  • Exchange
  • EDSA Nasdaq
  • HYFM Nasdaq
  • Market Cap
  • EDSA 13.8M
  • HYFM 16.0M
  • IPO Year
  • EDSA N/A
  • HYFM 2020
  • Fundamental
  • Price
  • EDSA $2.03
  • HYFM $3.79
  • Analyst Decision
  • EDSA Strong Buy
  • HYFM Hold
  • Analyst Count
  • EDSA 2
  • HYFM 2
  • Target Price
  • EDSA $13.00
  • HYFM $7.00
  • AVG Volume (30 Days)
  • EDSA 33.4K
  • HYFM 10.3K
  • Earning Date
  • EDSA 08-08-2025
  • HYFM 08-07-2025
  • Dividend Yield
  • EDSA N/A
  • HYFM N/A
  • EPS Growth
  • EDSA N/A
  • HYFM N/A
  • EPS
  • EDSA N/A
  • HYFM N/A
  • Revenue
  • EDSA N/A
  • HYFM $176,650,000.00
  • Revenue This Year
  • EDSA N/A
  • HYFM $5.45
  • Revenue Next Year
  • EDSA N/A
  • HYFM $5.33
  • P/E Ratio
  • EDSA N/A
  • HYFM N/A
  • Revenue Growth
  • EDSA N/A
  • HYFM N/A
  • 52 Week Low
  • EDSA $1.55
  • HYFM $1.50
  • 52 Week High
  • EDSA $5.59
  • HYFM $8.55
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 52.89
  • HYFM 50.79
  • Support Level
  • EDSA $1.91
  • HYFM $3.50
  • Resistance Level
  • EDSA $2.14
  • HYFM $3.83
  • Average True Range (ATR)
  • EDSA 0.12
  • HYFM 0.36
  • MACD
  • EDSA 0.02
  • HYFM -0.01
  • Stochastic Oscillator
  • EDSA 64.52
  • HYFM 36.28

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About HYFM Hydrofarm Holdings Group Inc.

Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.

Share on Social Networks: